BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF ROR-GAMMA

(19)

(11)

EP 3 408 268 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	06.12.2023 Bulletin 2023/49

(45)	Mention of the grant of the patent:
	04.08.2021 Bulletin 2021/31

(21)	Application number: 17703628.2

(22)	Date of filing: 27.01.2017

(51)

International Patent Classification (IPC):

C07D 405/06^(2006.01)
C07D 471/04^(2006.01)
C07D 233/90^(2006.01)
A61K 31/4433^(2006.01)
A61P 25/00^(2006.01)
A61P 35/00^(2006.01)

C07D 405/14^(2006.01)
C07D 233/88^(2006.01)
A61K 31/4184^(2006.01)
A61P 17/06^(2006.01)
A61P 29/00^(2006.01)

(52)

Cooperative Patent Classification (CPC):

C07D 405/14; C07D 233/88; C07D 233/90; C07D 405/06; C07D 471/04; A61P 1/04; A61P 1/16; A61P 1/18; A61P 11/00; A61P 11/02; A61P 11/06; A61P 15/00; A61P 17/00; A61P 17/02; A61P 17/04; A61P 17/06; A61P 19/02; A61P 19/08; A61P 21/00; A61P 21/04; A61P 25/00; A61P 25/08; A61P 25/14; A61P 25/18; A61P 25/24; A61P 25/28; A61P 27/02; A61P 29/00; A61P 3/04; A61P 35/00; A61P 5/00; A61P 5/14; A61P 9/02; A61P 9/12; A61P 3/10

(86)	International application number:
	PCT/US2017/015220

(87)	International publication number:
	WO 2017/132432 (03.08.2017 Gazette 2017/31)

(54)	BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF ROR-GAMMA BENZIMIDAZOLDERIVATIVE ALS MODULATOREN VON ROR-GAMMA DERIVES DE BENZIMIDAZOLE COMME DES MODULATEURS DE ROR-GAMMA

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
	Designated Extension States:
	BA ME
	Designated Validation States:
	MA MD

(30)

Priority:

29.01.2016 US 201662288487 P
11.04.2016 US 201662320893 P

(43)	Date of publication of application:
	05.12.2018 Bulletin 2018/49

(60)	Divisional application:
	21184347.9 / 3939974

(73)	Proprietor: Vitae Pharmaceuticals, LLC
	Madison, NJ 07940 (US)

(72)	Inventors:
	CLAREMON, David, A. Maple Glen PA 19002 (US) DILLARD, Lawrence, Wayne Yardley PA 19067 (US) FAN, Yi Doylestwon PA 18901 (US) LOTESTA, Stephen, D. Burlington NJ 08016 (US) SINGH, Suresh, B. Kendall Park NJ 08824 (US) TICE, Colin, M. Maple Glen PA 19002 (US) ZHAO, Wei North Potomac MD 20878 (US) ZHUANG, Linghang Chalfont PA 18914 (US)

(74)	Representative: Potter Clarkson
	Chapel Quarter Mount Street Nottingham NG1 6HQ Nottingham NG1 6HQ (GB)

(56)

References cited: :

WO-A1-2009/083526
WO-A1-2013/078233
US-B1- 6 348 032

WO-A1-2013/019682
WO-A1-2013/078240

SIME MAIRI ET AL: "Discovery of GSK1997132B a novel centrally penetrant benzimidazole PPAR[gamma] partial agonist", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 21, no. 18, 29 June 2011 (2011-06-29) , pages 5568-5572, XP029121377, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2011.06.088
BING YAN ET AL: "Quality control on combinatorial chemistry: Determination of the quantity, purity, and quantitative purity of compounds in combinatorial libraries", JOURNAL OF COMBINATORIAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US, vol. 5, no. 5, 1 January 2003 (2003-01-01) , pages 547-559, XP002413033, ISSN: 1520-4766, DOI: 10.1021/CC030008F
VOURLOUMIS D ET AL: "Solid-phase synthesis of benzimidazole libraries biased for RNA targets", TETRAHEDRON LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 44, no. 14, 31 March 2003 (2003-03-31), pages 2807-2811, XP004414453, ISSN: 0040-4039, DOI: 10.1016/S0040-4039(03)00453-2
LAMOTTE YANN ET AL: "Discovery of novel indazole derivatives as dual angiotensin II antagonists and partial PPAR[gamma] agon", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 24, no. 4, 2014, pages 1098-1103, XP028606704, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2014.01.004

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).